Loading
Pamrevlumab targeted the scar-like tissue around pancreatic tumours; its phase 3 LAPIS trial in locally advanced disease did not lengthen survival.
FibroGen developed pamrevlumab for fibrotic diseases and for pancreatic cancer, where connective tissue growth factor helps build the stroma that shields tumour cells. A phase 1/2 study suggested more patients could reach surgery.
The phase 3 LAPIS trial in locally advanced unresectable pancreatic cancer, combined with gemcitabine and nab-paclitaxel or FOLFIRINOX, did not meet its overall survival endpoint, reported in 2024. A metastatic arm within the Precision Promise platform trial was also stopped for futility, ending the programme.
Binds connective tissue growth factor, a driver of the dense fibrous stroma that surrounds pancreatic tumours, aiming to make them more resectable and more permeable to chemotherapy.
1.Pamrevlumab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pamrevlumab" OR ABSTRACT:"Pamrevlumab" OR TITLE:"FG-3019" OR ABSTRACT:"FG-3019") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamrevlumab, not a curated reading list.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.